UBS Group
CNTA

UBS Group’s Centessa Pharmaceuticals CNTA Stock Holding History

UBS Group’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.3M Sell
359,939
-177,579
-33% -$4.54M ﹤0.01% 2953
2025
Q4 		$13.4M Buy
537,518
+452,340
+531% +$11.5M ﹤0.01% 2983
2025
Q3 		$2.07M Sell
85,178
-124,572
-59% -$2.21M ﹤0.01% 4917
2025
Q2 		$2.76M Buy
209,750
+136,267
+185% +$1.73M ﹤0.01% 4483
2025
Q1 		$1.06M Sell
73,483
-996,726
-93% -$16.3M ﹤0.01% 5249
2024
Q4 		$17.9M Buy
1,070,209
+1,065,202
+21,274% +$17.6M ﹤0.01% 2445
2024
Q3 		$80.1K Buy
5,007
+2,198
+78% +$26.9K ﹤0.01% 6507
2024
Q2 		$25.4K Buy
2,809
+931
+50% +$8.83K ﹤0.01% 7149
2024
Q1 		$21.2K Buy
1,878
+295
+19% +$2.79K ﹤0.01% 6906
2023
Q4 		$12.6K Sell
1,583
-1,053
-40% -$7.06K ﹤0.01% 7341
2023
Q3 		$17.1K Buy
2,636
+518
+24% +$3.54K ﹤0.01% 6887
2023
Q2 		$13.1K Sell
2,118
-3,045
-59% -$14.4K ﹤0.01% 7048
2023
Q1 		$19.9K Buy
5,163
+2,577
+100% +$9.43K ﹤0.01% 7086
2022
Q4 		$8.02K Buy
2,586
+1,028
+66% +$3.81K ﹤0.01% 8829
2022
Q3 		$6K Buy
+1,558
New +$7.13K ﹤0.01% 9011
2022
Q1 		– Sell
-496
Closed -$6K – 10324
2021
Q4 		$6K Buy
496
+275
+124% +$3.7K ﹤0.01% 9257
2021
Q3 		$4K Sell
221
-457
-67% -$9.46K ﹤0.01% 8629
2021
Q2 		$15K Buy
+678
New +$15.9K ﹤0.01% 7638

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UBS Group's CNTA Position: Q1 2026 in Review

UBS Group reduced its Centessa Pharmaceuticals (CNTA) stake by 33% in Q1 2026, selling an estimated $4.54M and leaving 359,939 shares worth $14.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2953.

UBS Group first reported a position in CNTA in Q2 2021 and has held it in 18 quarters since. The position peaked at $17.9M in Q4 2024. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • UBS Group held 359,939 shares of Centessa Pharmaceuticals worth $14.3M as of Q1 2026.
  • UBS Group sold 177,579 Centessa Pharmaceuticals shares in Q1 2026, an estimated $4.54M.
  • Centessa Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #2953 holding.
  • UBS Group first reported a position in Centessa Pharmaceuticals in Q2 2021 and has held it in 18 quarters since.
  • UBS Group's Centessa Pharmaceuticals position peaked at $17.9M in Q4 2024.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.